German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88 ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third quarter ...